Phenylalanine
- Generic Name
- Phenylalanine
- Brand Names
- Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11NO2
- CAS Number
- 63-91-2
- Unique Ingredient Identifier
- 47E5O17Y3R
- Background
Phenylalanine is an essential aromatic amino acid that is a precursor of melanin, dopamine, noradrenalin (norepinephrine), and thyroxine.
- Indication
L-phenylalanine may be helpful in some with depression. It may also be useful in the treatment of vitiligo. There is some evidence that L-phenylalanine may exacerbate tardive dyskinesia in some schizophrenic patients and in some who have used neuroleptic drugs.
- Associated Therapies
- Amino acid supplementation
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Sapacitabine, Arm ADrug: Sapacitabine, Arm BDrug: Sapacitabine, Arm CDrug: sapacitabine, Arm EDrug: Sapacitabine, Arm GDrug: Sapacitabine, Arm HDrug: Sapacitabine, Arm I
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT00590187
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Vanderbilt U Medical Center, Nashville, Tennessee, United States
Bioequivalence and Food Effect Study in Healthy Volunteers
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- Drug: Formulation ADrug: Formulation BDrug: Formulation CDrug: Formulation EDrug: Formulation G
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00495274
- Locations
- 🇮🇹
GSK Investigational Site, Verona, Veneto, Italy
Effects of Aquamin F on Osteoarthritis of the Knee
- Conditions
- Osteoarthritis of the Knee
- First Posted Date
- 2007-03-26
- Last Posted Date
- 2007-03-26
- Lead Sponsor
- Marigot Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT00452101
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.